PARP-1-IN-3
Based on 1 Customer Validation
PARP-1-IN-3, a benzamide derivative, is a potent PARP-1 inhibitor with IC50 values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer.
For research use only. We do not sell to patients.
- Purity : 99.80%
- CAS No.: 2976342-33-1
- Formula: C21H17BrN2O3
- Molecular Weight:425.28
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PARP-1 0.25 nM (IC50) |
PARP-2 2.34 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DLD-1 | IC50 |
2.83 μM
Compound: 13f
|
Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36921527] |
| HCT-116 | IC50 |
0.3 μM
Compound: 13f
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36921527] |
| NCM460 | IC50 |
486.87 μM
Compound: 13f
|
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36921527] |
| SW480 | IC50 |
33.69 μM
Compound: 13f
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36921527] |
In Vitro
PARP-1-IN-3 (compound 13f; 48 h) has potent anticancer activity with IC50 values of 0.30, 2.83, 33.69, and 486.87 μM for HCT116, DLD-1, SW480, and NCM460 cells, respectively[1].
PARP-1-IN-3 (0.3-3 μM; 24-48 h) inhibits colony formation and migration of HCT116 cells[1].
PARP-1-IN-3 (0.3-3 μM; 48 h) induces accumulation of DNA double-strand breaks in HCT116 cells[1].
PARP-1-IN-3 (0.3-7.5 μM; 48-72 h) arrests cell cycle at G2/M phase, reduces mitochondrial membrane potential and ultimately induce apoptosis in HCT116 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 cells
-
Concentration:0.3, 1.5, 7.5 μM
-
Incubation Time:48 and 72 h
-
Result:Increased the percentage of total apoptotic cells from 1.05% (control group) to 79.49% (7.5 μM).
-
Cell Line:HCT116 cells
-
Concentration:0.3, 1.5, 7.5 μM
-
Incubation Time:48 and 72 h
-
Result:Blocked the cell cycle progression at G2/M phase.
-
Cell Line:HCT116 cells
-
Concentration:0.3, 1, 3 μM
-
Incubation Time:48 h
-
Result:Increased expression levels of γH2AX in a concentration-dependent manner.
-
Cell Line:HCT116 cells
-
Concentration:0.3, 1, 3 μM
-
Incubation Time:48 h
-
Result:Increased the expression levels of Bax, cleaved Caspase-3 and cleaved-PARP, and decreased the expression level of Bcl-2.
Chemical Information
-
CAS No. 2976342-33-1
-
Appearance Solid
-
Molecular Weight 425.28
-
Formula C21H17BrN2O3
-
Color White to light yellow
-
SMILES
NC(C1=CC=CC=C1OCC2=CC=CC(NC(C3=CC=C(C=C3)Br)=O)=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (293.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3514 mL | 11.7570 mL | 23.5139 mL | 58.7848 mL |
| 5 mM | 0.4703 mL | 2.3514 mL | 4.7028 mL | 11.7570 mL | |
| 10 mM | 0.2351 mL | 1.1757 mL | 2.3514 mL | 5.8785 mL | |
| 15 mM | 0.1568 mL | 0.7838 mL | 1.5676 mL | 3.9190 mL | |
| 20 mM | 0.1176 mL | 0.5878 mL | 1.1757 mL | 2.9392 mL | |
| 25 mM | 0.0941 mL | 0.4703 mL | 0.9406 mL | 2.3514 mL | |
| 30 mM | 0.0784 mL | 0.3919 mL | 0.7838 mL | 1.9595 mL | |
| 40 mM | 0.0588 mL | 0.2939 mL | 0.5878 mL | 1.4696 mL | |
| 50 mM | 0.0470 mL | 0.2351 mL | 0.4703 mL | 1.1757 mL | |
| 60 mM | 0.0392 mL | 0.1959 mL | 0.3919 mL | 0.9797 mL | |
| 80 mM | 0.0294 mL | 0.1470 mL | 0.2939 mL | 0.7348 mL | |
| 100 mM | 0.0235 mL | 0.1176 mL | 0.2351 mL | 0.5878 mL |